NCT06991114Phase 2Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Study sponsor: Artiva Biotherapeutics, Inc. · ARTV

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-01Estimated
Enrollment · participants90Estimated
Source updated2026-07-31Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.